Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press109510.17650/1726-9776-2008-4-2-16-21DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак почкиApoptosis and proliferation factors in renal canceФакторы апоптоза и пролиферации при раке почкиLoranO. B.ЛоранО. Б.
Russian Federation
FrankG. A.ФранкГ. А.
Russian Federation

Moscow

Москва

SereginA. V.СерегинА. В.
Russian Federation
ZavalishinaL. E.ЗавалишинаЛ. Э.
Russian Federation

Moscow

Москва

AndreevaU. U.АндрееваЮ. Ю.
Russian Federation

Moscow

Москва

SereginA. A.СерегинА. А.
Russian Federation
ShustitzkiyN. A.ШустицкийН. А.
Russian Federation
Urology and surgical andrology department of russian medical academy of the post-diploma educationКафедра урологии и хирургической андрологии ГОУ ДПО РМАПОMoscow research oncology institute named after P.A. GercenФГУ МНИОИ им. П.А. Герцена Росмедтехнологий300620084216211502202015022020https://oncourology.abvpress.ru/oncur/article/view/1095

The problem of forecasting of a kidney cancer and a choice of a method of adjuvant treatment the advanced forms of this disease remains actual. In the given research the estimation of prognostic importance of apoptotic and proliferative markers in 66 patients with local advanсed and metastatic renal cell carcinoma has been led. Results of the work allow to conclude that the estimation of expression of these markers allows to allocate groups of patients of the high risk requiring careful supervision and treatment.

.

1. Чиссов В.И., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2004 году. М.; 2005.Чиссов В.И., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2004 году. М.; 2005.2. Mathew A., Devesa S.S., Fraumeni J.F. Jr. et al. Global increases in kidney cancer incidence, 1973–92. Eur J Cancer Prev 2002;11:171–8.Mathew A., Devesa S.S., Fraumeni J.F. Jr. et al. Global increases in kidney cancer incidence, 1973–92. Eur J Cancer Prev 2002;11:171–8.3. Flanigan R.C., Campbell S.C., Clark J.I. et al. Metastatic renal cell carcinoma. Current treatment options. Oncology 2003;4:385–90.Flanigan R.C., Campbell S.C., Clark J.I. et al. Metastatic renal cell carcinoma. Current treatment options. Oncology 2003;4:385–90.4. Mickisch G.H. Rational selection of a control arm for randomised trials in metastatic renal cell carcinoma. Eur Urol 2003;43:670–9.Mickisch G.H. Rational selection of a control arm for randomised trials in metastatic renal cell carcinoma. Eur Urol 2003;43:670–9.5. Linechan S.H., Shipley W.U., Parkinson D.R. Cancer of the kidney and ureter. In: De Vita V.T. Ir., Ed. Cancer: principles and practice of oncology, 4th ed. Philadelphia, J.B. Lippincot; 1993.Linechan S.H., Shipley W.U., Parkinson D.R. Cancer of the kidney and ureter. In: De Vita V.T. Ir., Ed. Cancer: principles and practice of oncology, 4th ed. Philadelphia, J.B. Lippincot; 1993.6. Гарин А.М., Хлебнов А.В. Справочник практической химиотерапии опухолей. М., Росмэн; 1995.Гарин А.М., Хлебнов А.В. Справочник практической химиотерапии опухолей. М., Росмэн; 1995.7. Amato R.J. Chemotherapy for renal cell carcinoma. Semin Oncol 2000;27:177–86.Amato R.J. Chemotherapy for renal cell carcinoma. Semin Oncol 2000;27:177–86.8. Fossa S., Droz J.P., Pavone-Macaluso M. et al. Vinblastine in Metastatic Renal Cell Carcinoma: EORTC Phase III Trial 30882. Eur J Cancer 1992;28a:878–80.Fossa S., Droz J.P., Pavone-Macaluso M. et al. Vinblastine in Metastatic Renal Cell Carcinoma: EORTC Phase III Trial 30882. Eur J Cancer 1992;28a:878–80.9. Yagoda A., Abi-Rached B., Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol 1995;22:42–60.Yagoda A., Abi-Rached B., Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol 1995;22:42–60.10. Pyrhönen S., Salminen E., Ruutu M. et al. Prospective Randomized Trial of Interferon Alfa-2a Plus Vinblastine Versus Vinblastine Alone in Patients With Advanced Renal Cell Carcinoma. J Clin Oncol 1999;17:2859–70.Pyrhönen S., Salminen E., Ruutu M. et al. Prospective Randomized Trial of Interferon Alfa-2a Plus Vinblastine Versus Vinblastine Alone in Patients With Advanced Renal Cell Carcinoma. J Clin Oncol 1999;17:2859–70.11. Steiner G., Strander H., Carbin B.E. et al. Recombinante interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomised trial. Acta Oncol 1990;29:155.Steiner G., Strander H., Carbin B.E. et al. Recombinante interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomised trial. Acta Oncol 1990;29:155.12. Papac R.J., Keohane M.F. Hormonal therapy for metastatic renal cell carcinoma combined androgent and prover followed by high dose tamoxifen. Eur J Cancer 1993;29:997–9.Papac R.J., Keohane M.F. Hormonal therapy for metastatic renal cell carcinoma combined androgent and prover followed by high dose tamoxifen. Eur J Cancer 1993;29:997–9.13. Bone Pain Trial Working Party. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient followup. Radiother Oncol 1999;52:111–21.Bone Pain Trial Working Party. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient followup. Radiother Oncol 1999;52:111–21.14. Huguenin P.U., Kieser S., Glanzmann C. et al. Radiotherapy for metastatic carcinomas of the kidney or melanomas: an analysis using palliative end points. Int J Rad Oncol Biol Phys 1998;41:401–5.Huguenin P.U., Kieser S., Glanzmann C. et al. Radiotherapy for metastatic carcinomas of the kidney or melanomas: an analysis using palliative end points. Int J Rad Oncol Biol Phys 1998;41:401–5.15. Tretter C.P.G., Ernstoff M.S. Chemotherapy, Hormonal therapy, and Interferons. Genitourinary Oncology, 2nd ed. Edited by N.J. Vogelzang, P.T. Scarding, W.U. Shipley, D.S. Coffey. USA, Lippincott Williams and Wilkins; 1999. p. 248–59.Tretter C.P.G., Ernstoff M.S. Chemotherapy, Hormonal therapy, and Interferons. Genitourinary Oncology, 2nd ed. Edited by N.J. Vogelzang, P.T. Scarding, W.U. Shipley, D.S. Coffey. USA, Lippincott Williams and Wilkins; 1999. p. 248–59.16. Kim H.L., Seligson D., Liu X. et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 2005;73(5):1496–501.Kim H.L., Seligson D., Liu X. et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 2005;73(5):1496–501.17. Vasavada S.P., Novick A.C., Williams B.R. P53, Bcl-2, and Bax expression in renal cell carcinoma. Urology 1998;51:1057–61.Vasavada S.P., Novick A.C., Williams B.R. P53, Bcl-2, and Bax expression in renal cell carcinoma. Urology 1998;51:1057–61.18. Uzunlar A.K., Sahin H., Yilmaz F. et al. Expression of p53 oncoprotein and Bcl-2 in renal cell carcinoma. Saudi Med J 2005;26:37–41.Uzunlar A.K., Sahin H., Yilmaz F. et al. Expression of p53 oncoprotein and Bcl-2 in renal cell carcinoma. Saudi Med J 2005;26:37–41.19. Cho D.S., Joo H.J., Oh D.K. et al. Cyclooxygenase-2 and p53 expression as prognostic indicators in conventional renal cell carcinoma. Yonsei Med J 2005;46(1):133–40.Cho D.S., Joo H.J., Oh D.K. et al. Cyclooxygenase-2 and p53 expression as prognostic indicators in conventional renal cell carcinoma. Yonsei Med J 2005;46(1):133–40.